Hyaluronan

Introduction Overview

Generic Name

hyaluronan

Brand Name

Orthovisc

Dosage Form

Intra-articular injectable solution

Drug Class

Viscosupplementation agents

Pharmacokinetics

Absorption:
Orthovisc is administered via intra-articular injection directly into the synovial fluid of the knee joint, thereby bypassing gastrointestinal and systemic absorption pathways. Due to this local administration, systemic absorption is minimal. Any absorbed hyaluronan undergoes rapid clearance from the systemic circulation. The direct joint administration allows Orthovisc to exert localized effects within the joint cavity without significant systemic exposure.

Distribution:
Once injected into the joint space, hyaluronan disperses within the synovial fluid and integrates with endogenous hyaluronate molecules contributing to the viscoelastic properties essential for joint lubrication and shock absorption. Distribution is largely confined to the joint cavity, and systemic distribution is negligible. The exogenous hyaluronan enhances the physical properties of the synovial fluid, restoring its normal function impaired in osteoarthritis.

Metabolism:
Hyaluronan is metabolized primarily by enzymatic degradation through hyaluronidases present within the joint and reticuloendothelial system. These enzymes cleave the high molecular weight polymer into smaller oligosaccharide fragments, which are subsequently taken up by lymphatic and vascular systems for further degradation. The metabolic products are eventually broken down into carbon dioxide and water or reused in cellular functions.

Elimination:
Following enzymatic degradation, the metabolic fragments are eliminated through lymphatic drainage and systemic circulation with renal excretion as the terminal step. The elimination half-life within the joint space is influenced by molecular weight and the degree of cross-linking of the hyaluronan preparation. Orthovisc, with its specific high molecular weight formulation, may have an intra-articular residence time sufficient to provide symptomatic relief lasting several months, delaying the need for subsequent injections.

Dosage Forms

Available Dosage Forms:
- Orthovisc is supplied as a sterile 2 mL intra-articular injectable solution.
- The formulation is intended specifically for injection into the knee joint capsule.
- The preparation is preservative-free and designed for single-use application.

Dosages for Adults and Adolescents:
- The standard adult dosing regimen for osteoarthritis of the knee is 2 mL injected intra-articularly once weekly for a total of 3 to 4 weeks.
- The injections are spaced at least one week apart.
- If joint effusion is present prior to injection, aspiration should be performed to remove excess fluid.
- A new sterile syringe should be used for each injection to minimize infection risk.
- Orthovisc is not approved for use in individuals younger than 21 years of age, reflecting limited safety and efficacy data in pediatric populations.

Specific Patient Populations:
- Use in pregnant or breastfeeding women is not well studied; healthcare providers must evaluate risk versus benefit due to unknown systemic exposure effects.
- Patients with bleeding or clotting disorders require careful assessment prior to administration owing to injection-related bleeding risks.
- Individuals with active knee or periarticular infections or allergies to hyaluronan or gram-positive bacterial proteins are contraindicated.
- No dose adjustment is generally necessary for elderly patients; however, clinical judgment should be applied based on comorbidities and joint condition.

Mechanism Of Action

Orthovisc functions by supplementing the viscosity and elasticity of synovial fluid within the knee joint through administration of exogenous high molecular weight hyaluronan, a naturally occurring glycosaminoglycan and major component of the extracellular matrix. In osteoarthritis, endogenous hyaluronan concentration and quality are diminished, leading to decreased joint lubrication and increased friction during movement.

Upon injection, Orthovisc enhances the viscoelasticity of the synovial fluid, restoring its lubricating and shock-absorbing capabilities. This mechanical effect reduces joint stress and may slow cartilage degradation associated with osteoarthritis. Additionally, hyaluronan modulates chondrocyte function and extracellular matrix metabolism, contributing to the maintenance of cartilage integrity.

Molecularly, hyaluronan interacts with cell surface receptors such as CD44 and RHAMM (Receptor for Hyaluronic Acid Mediated Motility), influencing inflammatory pathways and cell signaling mechanisms that can reduce synovial inflammation and pain perception. These biochemical interactions may contribute to analgesic effects independent of the purely mechanical properties.

Comparatively, Orthovisc differs from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids by providing a disease-modifying approach rather than targeting only inflammation or pain pathways. Clinical evidence supports its use as an adjunct or alternative therapy, particularly following inadequate response to pharmacologic agents, with a relatively favorable safety profile owing to its localized joint administration and minimal systemic effects.

Pharmacological Actions

Acts as a viscosupplement to restore viscoelastic properties of synovial fluid in osteoarthritic joints.
Provides lubrication and shock absorption within the knee joint, reducing mechanical stress on articular cartilage.
Modulates chondrocyte metabolism to support cartilage health and repair.
Interacts with cell surface receptors influencing inflammatory and pain signaling pathways.
Exerts potential anti-inflammatory effects by reducing synovial membrane irritation.
Enhances joint mobility and reduces stiffness by improving synovial fluid function.
Possesses a low systemic absorption profile, leading to a healthier safety profile compared to systemic agents.
Delays need for more invasive treatments such as total knee replacement surgery in osteoarthritis patients.
May improve quality of life through reduction in pain and functional impairment.
Does not exhibit the gastrointestinal or cardiovascular adverse effects associated with oral NSAIDs.
Produces sustained symptom relief, potentially lasting several months after a course of injections.

Therapeutic Or Clinical Uses

Management of knee pain and functional impairment due to osteoarthritis.
Adjunct therapy for patients who have inadequate response to oral analgesics or NSAIDs.
Viscosupplementation to restore joint fluid dynamics in degenerative joint conditions.
Treatment alternative for patients unable to tolerate systemic anti-inflammatory medications.
Reduction of joint stiffness and improvement of mobility associated with cartilage degradation.
Potential delay of surgical interventions including total knee arthroplasty.
Used in patients with moderate to severe osteoarthritis where conservative treatments have failed.
Symptom relief in osteoarthritis patients aiming to maintain activity levels and quality of life.
Occasionally employed in other joint degenerative conditions off-label, pending clinical discretion.
May reduce joint effusion by improving synovial fluid function.
Implemented as part of a multimodal approach to osteoarthritis management including physical therapy and lifestyle modifications.

Side Or Adverse Effects

Injection site reactions such as pain, swelling, redness, or mild discomfort.
Transient joint stiffness or pain following injection.
Itching, numbness, or tingling sensations around the injection area.
Possible headache or dizziness post-administration.
Back pain reported in some patients during treatment course.
Inflammatory reactions within the joint including swelling or warmth.
Rare risk of allergic reactions including urticaria or anaphylaxis.
Increased knee pain or exacerbation of symptoms in some cases.
Signs of infection at or near the injection site, including redness and tenderness.
Bleeding or bruising associated with injection site, particularly in patients with clotting disorders.
Generalized hypersensitivity to hyaluronan or bacterial protein components leading to severe reactions.
Potential for synovitis and effusion flare-ups post injection.
Mild systemic effects are rare due to minimal systemic exposure.
Patients may experience discomfort necessitating symptomatic treatment.
Delayed hypersensitivity reactions have been rarely documented.

Precautions

Do not administer Orthovisc to patients with known allergies to hyaluronan or gram positive bacterial proteins.
Avoid use in patients with bleeding or clotting disorders such as hemophilia due to injection-related bleeding risk.
Contraindicated in presence of active knee joint or overlying skin infection.
Use caution in pregnant or breastfeeding women given lack of clinical safety data.
Not recommended for use in patients under 21 years of age due to insufficient safety and efficacy data.
Ensure joint effusion is aspirated prior to injection to reduce risk of adverse effects.
Maintain strict aseptic technique during injection to prevent septic arthritis.
Monitor patients for allergic reactions during and after administration.
Advise patients to avoid strenuous activity or weight-bearing for at least 48 hours post injection.
Monitor patients with compromised immune systems closely for injection site infections.
Assess for hypersensitivity reactions during first treatment session.
Inform patients about importance of adhering to scheduled injection intervals.
Avoid concurrent use with other intra-articular therapies unless specifically directed.
Use cautiously in patients with severe joint deformities or instability.
Educate patients to report any worsening joint symptoms promptly.

Warnings

Orthovisc must not be given to individuals allergic to hyaluronate formulations or gram positive bacterial proteins.
Contraindicated in patients with infection in the knee joint or in the skin surrounding the knee.
Risk of serious allergic reactions including anaphylaxis; immediate medical attention required if symptoms occur.
Injection-related infections can lead to septic arthritis; aseptic techniques are critical during administration.
Use caution in patients with bleeding disorders due to increased risk of hematoma at the injection site.
Orthovisc is not approved for use in pediatric patients below 21 years of age due to safety concerns.
Pregnancy and lactation safety have not been established; use only if clearly needed by physician.
Avoid high-impact sports and strenuous activities for at least 48 hours after injection to prevent joint injury.
Discontinue treatment if patient exhibits severe local inflammatory reactions or systemic hypersensitivity.
Monitor for increased joint pain or swelling post injection, which may require medical evaluation.
Not recommended as a first-line therapy; typically reserved for patients unresponsive to standard pharmacologic treatments.
Potential for injection site hemorrhage especially in anticoagulated patients.
Risk-benefit ratio should be assessed in patients with compromised immune systems.
Patients should be counseled on signs of infection and allergic reactions prior to therapy.

Contraindication

Known hypersensitivity or allergy to hyaluronan or components of Orthovisc.
Allergy to gram positive bacterial proteins used in hyaluronan production.
Active infection of the knee joint or skin overlying the injection site.
Bleeding or clotting disorders such as hemophilia increasing risk of injection site bleeding.
Patients younger than 21 years due to insufficient safety and efficacy data.
Should not be given during acute joint inflammation unrelated to osteoarthritis (e.g., rheumatoid arthritis flare).
Contraindicated in cases of known hypersensitivity to any ingredient of Orthovisc formulation.
Patients with open wounds or damaged skin at injection site.
Severe deformity or instability of the knee joint where injection could exacerbate symptoms.
Patients with septic arthritis or suspected joint infection.
Individuals with active systemic infections until adequately treated.

Drug Interactions

Potential interactions with other intra-articular therapies are not well studied; caution is advised.
No significant systemic drug interactions reported due to localized administration and minimal systemic absorption.
Concomitant use with anticoagulant therapy may increase risk of bleeding or hematoma at injection sites.
Use with caution in patients receiving immunosuppressive therapies due to potential infection risk.
No known interactions with oral analgesics, NSAIDs, or corticosteroids.
Interaction with supplements such as glucosamine or chondroitin has not been fully established.
Avoid concurrent administration with other viscosupplementation agents in the same joint.
Interactions with herbal products are not documented but caution is advised with agents affecting coagulation.
Patients should inform providers about all medications to assess potential risks before injection.
No reported pharmacokinetic drug-drug interactions due to local injection route.
No documented interference with laboratory tests or diagnostic imaging.
Potential additive effects on joint irritation when combined with intra-articular corticosteroids.
Concurrent infection treatments should be completed prior to Orthovisc administration.
Providers should monitor for unusual reactions when Orthovisc is used in polypharmacy patients.
Drug interaction profile considered minimal but vigilance is recommended.

Preparations Of The Drug

Orthovisc is provided as a sterile, single-use 2 mL prefilled syringe containing hyaluronan injection.
The formulation is preservative-free to reduce risk of injection site reactions and contamination.
Prepared under aseptic conditions to maintain sterility and stability of the high molecular weight hyaluronan.
Available specifically for intra-articular injection in the knee joint.
Storage recommended at controlled room temperature avoiding extreme heat or freezing conditions.
Each syringe is designed for single administration to prevent cross-contamination and infection risks.
Packaging includes detailed instructions for use and handling by healthcare professionals.
No added antimicrobials or steroids are present in the formulation.
The drug is supplied with sterile, disposable needles suitable for intra-articular administration.
Lot numbers and expiration dates are clearly labeled to ensure product integrity.
Manufactured to meet quality standards specific to viscosupplementation agents.
Instructions emphasize use within recommended dosing intervals and proper injection techniques.
Discard any unused portion after administration to maintain safety and efficacy.
Patient information leaflets accompany each package outlining potential side effects and precautions.
Not intended for systemic intravenous or intramuscular administration.